Fiche du document
- doi: 10.1007/s40263-018-0509-5
- issn: 1172-7047
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40263-018-0509-5
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29582404
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1179-1934
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D4180DD604D84
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
I. Beuchat et al., « Newer Antiepileptic Drugs for Status Epilepticus in Adults: What's the Evidence? », Serveur académique Lausannois, ID : 10.1007/s40263-018-0509-5
Métriques
Partage / Export
Résumé
Status epilepticus (SE) is one of the most frequent neurological emergencies. Despite this, understanding of its pathophysiology and evidence regarding its management is limited. Rapid, effective, and well-tolerated treatment to achieve seizure cessation is advocated to prevent brain damage or potentially lethal outcomes. The last two decades have witnessed an exponential increase in the number of available antiepileptic drugs (AEDs). These compounds, especially lacosamide and levetiracetam, in view of their intravenous formulation, have been increasingly prescribed in SE. These and other newer AEDs present a promising profile in terms of tolerability, with few centrally depressive effects, favorable pharmacokinetic properties, and fewer drug interactions than classical AEDs; conversely, they are more expensive. There is still no clear evidence to suggest a specific beneficial impact of newer AEDs on SE outcome, preventing any strong recommendation regarding their prescription in SE. Further comparative studies are urgently required to clarify their place and optimal use in the armamentarium of SE treatment.